nach oben

Erschienen in:

04.10.2021 | Original articles

Association of CHA₂DS₂-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI

verfasst von: Orhan Maden, MD, Özge Çakmak Karaaslan, MD, Yücel Kanal, MD, İdris Yakut, MD, Nezaket Merve Yaman, MD, Hasan Can Könte, MD, Kevser Gülcihan Balcı, MD, Mehmet Timur Selçuk, MD, Hatice Selçuk, MD

Erschienen in: Herz | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

The rate of saphenous vein graft (SVG) occlusion within the first year of bypass graft surgery is 15%. The CHA₂DS₂-VASc score is used to predict the risk of thromboembolic events in patients with nonvalvular atrial fibrillation. We aimed to evaluate the predictive role of the CHA₂DS₂-VASc score in the estimation of intracoronary thrombus burden in patients with acute myocardial infarction (AMI) who underwent SVG-PCI.

Methods

We retrospectively evaluated 221 patients who were admitted with AMI and underwent PCI of SVGs at the Department of Cardiology in the Turkiye Yuksek Ihtisas Education and Research Hospital between 2012 and 2018. The study population was divided into two groups according to their Thrombolysis in Myocardial Infarction (TIMI) thrombus grade: low thrombus burden (LTB; TIMI 0–3) and high thrombus burden (HTB; TIMI 4 and 5).

Results

The study included 221 patients with a mean age of 63.3 ± 6.7 years. The patients with HTB had significantly higher CHA₂DS₂-VASc scores (p < 0.001) compared with LTB patients. Univariate and multivariate regression analysis demonstrated that both CHA₂DS₂-VASc score (OR: 1.573, 95% CI: 1.153–2.147, p = 0.004) as a continuous variable and a binary cut-off level of the CHA₂DS₂-VASc score > 3 (OR: 3.876, 95% CI: 1.705–8.808, p = 0.001) were significantly associated with HTB. The ability of the CHA₂DS₂-VASc score to predict HTB burden was evaluated by receiver-operating characteristics analysis curve analysis. The optimum cut-off value of the CHA₂DS₂-VASc score for predicting HTB was 3 (with a sensitivity of 67.9% and a specificity of 69.3%) according to the Youden index.

Conclusion

The CHA₂DS₂-VASc score can be used as an easy practical tool to predict HTB in AMI patients undergoing SVG-PCI.

Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA et al (2009) Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med 361:235–244. https://doi.org/10.1056/NEJMoa0900708CrossRefPubMed

Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al (2019) 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 40:87–165. https://doi.org/10.1093/eurheartj/ehy394CrossRefPubMed

Lee MS, Park SJ, Kandzari DE, Kirtane AJ, Fearon WF, Brilakis ES et al (2011) Saphenous vein graft intervention. JACC Cardiovasc Interv 4:831–843. https://doi.org/10.1016/j.jcin.2011.05.014CrossRefPubMed

Owens CD (2010) Adaptive changes in autogenous vein grafts for arterial reconstruction: clinical implications. J Vasc Surg 51:736–746. https://doi.org/10.1016/j.jvs.2009.07.102CrossRefPubMed

Parang P, Arora R (2009) Coronary vein graft disease: pathogenesis and prevention. Can J Cardiol 25:e57–62. https://doi.org/10.1016/s0828-282x(09)70486-6CrossRefPubMedPubMedCentral

Campeau L, Enjalbert M, Lespérance J, Bourassa MG, Kwiterovich P Jr., Wacholder S et al (1984) The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 311:1329–1332. https://doi.org/10.1056/nejm198411223112101CrossRefPubMed

Motwani JG, Topol EJ (1998) Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97:916–931. https://doi.org/10.1161/01.cir.97.9.916CrossRefPubMed

Brilakis ES, Rao SV, Banerjee S, Goldman S, Shunk KA, Holmes DR Jr. et al (2011) Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the national cardiovascular data registry. JACC Cardiovasc Interv 4:844–850. https://doi.org/10.1016/j.jcin.2011.03.018CrossRefPubMed

Dash D (2014) An update on coronary bypass graft intervention. Heart Asia 6:41–45. https://doi.org/10.1136/heartasia-2013-010478CrossRefPubMedPubMedCentral

10.

Cameron A, Kemp HG Jr., Green GE (1988) Reoperation for coronary artery disease. 10 years of clinical follow-up. Circulation 78:I158–162PubMed

11.

O’Connor GT, Malenka DJ, Quinton H, Robb JF, Kellett MA Jr., Shubrooks S et al (1999) Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994–1996. Northern New England cardiovascular disease study group. J Am Coll Cardiol 34:681–691. https://doi.org/10.1016/s0735-1097(99)00267-3CrossRefPubMed

12.

Kirtane AJ, Heyman ER, Metzger C, Breall JA, Carrozza JP Jr. (2008) Correlates of adverse events during saphenous vein graft intervention with distal embolic protection: a PRIDE substudy. JACC Cardiovasc Interv 1:186–191. https://doi.org/10.1016/j.jcin.2008.01.002CrossRefPubMed

13.

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr. et al (2019) 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Heart Rhythm 16:e66–e93. https://doi.org/10.1016/j.hrthm.2019.01.024CrossRefPubMed

14.

Chua SK, Lo HM, Chiu CZ, Shyu KG (2014) Use of CHADS₂ and CHA₂DS₂-VASc scores to predict subsequent myocardial infarction, stroke, and death in patients with acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry. PLoS One 9:e111167. https://doi.org/10.1371/journal.pone.0111167CrossRefPubMedPubMedCentral

15.

Satılmış S, Durmuş G (2020) Predictive accuracy of CHA(2)DS(2)-VASc score in determining the high thrombus burden in patients with non-ST-elevation myocardial infarction. Acta Cardiol. https://doi.org/10.1080/00015385.2019.1707934CrossRefPubMed

16.

Ipek G, Onuk T, Karatas MB, Gungor B, Osken A, Keskin M et al (2016) CHA2DS2-VASc score is a predictor of no-reflow in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous intervention. Angiology 67:840–845. https://doi.org/10.1177/0003319715622844CrossRefPubMed

17.

Keskin K, Sezai Yıldız S, Çetinkal G, Aksan G, Kilci H, Çetin Ş et al (2017) The value of CHA(2)DS(2)VASC score in predicting all-cause mortality in patients with ST-segment elevation myocardial infarction who have undergone primary Percutaneous coronary intervention. Acta Cardiol Sin 33:598–604. https://doi.org/10.6515/acs20170723aCrossRefPubMedPubMedCentral

18.

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA et al (2018) Fourth universal definition of myocardial infarction. J Am Coll Cardiol 72:2231–2264. https://doi.org/10.1016/j.jacc.2018.08.1038CrossRefPubMed

19.

Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur Heart J 31:2369–2429. https://doi.org/10.1093/eurheartj/ehq278CrossRefPubMed

20.

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al (2005) Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber Quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr 18:1440–1463. https://doi.org/10.1016/j.echo.2005.10.005CrossRefPubMed

21.

Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F et al (2016) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 37:267–315. https://doi.org/10.1093/eurheartj/ehv320CrossRefPubMed

22.

Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP et al (2001) Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 103:2550–2554. https://doi.org/10.1161/01.cir.103.21.2550CrossRefPubMed

23.

Niccoli G, Burzotta F, Galiuto L, Crea F (2009) Myocardial no-reflow in humans. J Am Coll Cardiol 54:281–292. https://doi.org/10.1016/j.jacc.2009.03.054CrossRefPubMed

24.

Falk E, Thuesen L (2003) Pathology of coronary microembolisation and no reflow. Heart 89:983–985. https://doi.org/10.1136/heart.89.9.983CrossRefPubMedPubMedCentral

25.

Ellis SG, Lincoff AM, Miller D, Tcheng JE, Kleiman NS, Kereiakes D et al (1998) Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG investigators. Evaluation of 7E3 for the prevention of Ischemic complications. Evaluation of PTCA to improve long-term outcome with abciximab GPIIb/IIIa receptor blockade. J Am Coll Cardiol 32:1619–1623. https://doi.org/10.1016/s0735-1097(98)00403-3CrossRefPubMed

26.

Fernández-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A et al (1994) Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 23:1562–1569. https://doi.org/10.1016/0735-1097(94)90657-2CrossRefPubMed

27.

Tanboga IH, Topcu S, Aksakal E, Kalkan K, Sevimli S, Acikel M (2014) Determinants of angiographic thrombus burden in patients with ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost 20:716–722. https://doi.org/10.1177/1076029613483169CrossRefPubMed

28.

Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE et al (2002) Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 105:1285–1290CrossRef

29.

Wang X, Pei C, Bai Y, Dai Q, Deng X, Liu Y et al (2019) Predictive value of CHA(2)DS(2)-VASc score for ischemic events in patients undergoing percutaneous coronary intervention. Angiology 70:878–886. https://doi.org/10.1177/0003319718804661CrossRefPubMed

30.

Huang FY, Huang BT, Pu XB, Yang Y, Chen SJ, Xia TL et al (2017) CHADS(2), CHA(2)DS(2)-VASc and R(2)CHADS(2) scores predict mortality in patients with coronary artery disease. Intern Emerg Med 12:479–486. https://doi.org/10.1007/s11739-017-1608-xCrossRefPubMed

31.

Biancari F, Asim Mahar MA, Kangasniemi OP (2013) CHADS2 and CHA2DS2-VASc scores for prediction of immediate and late stroke after coronary artery bypass graft surgery. J Stroke Cerebrovasc Dis 22:1304–1311. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.11.004CrossRefPubMed

32.

Mirbolouk F, Gholipour M, Salari A, Shakiba M, Kheyrkhah J, Nikseresht V et al (2018) CHA2DS2-VASc score predict no-reflow phenomenon in primary percutaneous coronary intervention in primary percutaneous coronary intervention. J Cardiovasc Thorac Res 10:46–52. https://doi.org/10.15171/jcvtr.2018.08CrossRefPubMedPubMedCentral

33.

Oikonomou E, Mourouzis K, Vogiatzi G, Siasos G, Deftereos S, Papaioannou S et al (2018) Coronary microcirculation and the no-reflow phenomenon. CPD 24:2934–2942. https://doi.org/10.2174/1381612824666180911122230CrossRef

34.

Durante A, Camici PG (2015) Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol 187:273–280. https://doi.org/10.1016/j.ijcard.2015.03.359CrossRefPubMed

35.

Di Carli MF, Janisse J, Grunberger G, Ager J (2003) Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 41:1387–1393. https://doi.org/10.1016/s0735-1097(03)00166-9CrossRefPubMed

36.

Ashoori A, Pourhosseini H, Ghodsi S, Salarifar M, Nematipour E, Alidoosti M et al (2019) CHA2DS2-VASc score as an independent predictor of suboptimal reperfusion and short-term mortality after primary PCI in patients with acute ST segment elevation myocardial infarction. Medicina. https://doi.org/10.3390/medicina55020035CrossRefPubMedPubMedCentral

37.

Duman H, Çinier G, Bakırcı EM, Duman H, Şimşek Z, Hamur H et al (2019) Relationship between C‑reactive protein to albumin ratio and thrombus burden in patients with acute coronary syndrome. Clin Appl Thromb Hemost 25:1076029618824418. https://doi.org/10.1177/1076029618824418CrossRefPubMedPubMedCentral

38.

Eid-Lidt G, Gaspar J, Adames AE, Damas de Los Santos F, Valdez RI, Ramírez-Gutiérrez AE et al (2010) Long-term outcomes of saphenous vein graft stenting compared with native coronary artery stenting in patients with previous coronary artery bypass graft surgery. Arch Cardiol Mex 80:3–9PubMed

39.

Sdringola S, Assali AR, Ghani M, Moustapha A, Achour H, Yusuf SW et al (2001) Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheter Cardiovasc Interv 54:318–324. https://doi.org/10.1002/ccd.1290CrossRefPubMed

40.

Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y et al (1995) Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 130:239–243. https://doi.org/10.1016/0002-8703(95)90434-4CrossRefPubMed

41.

Bayramoğlu A, Taşolar H, Kaya A, Tanboğa İH, Yaman M, Bektaş O et al (2018) Prediction of no-reflow and major adverse cardiovascular events with a new scoring system in STEMI patients. J Interven Cardiol 31:144–149. https://doi.org/10.1111/joic.12463CrossRef

42.

Gürbak İ, Panç C, Şahin AA, Derviş E, Yıldız İ, Güler A et al (2020) CHA2DS2-VASc score as a predictor of no-reflow phenomenon after saphenous vein graft percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Kardiol Pol 78:1129–1136. https://doi.org/10.33963/kp.15603CrossRefPubMed

43.

Yip HK, Chen MC, Chang HW, Hang CL, Hsieh YK, Fang CY et al (2002) Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest 122:1322–1332. https://doi.org/10.1378/chest.122.4.1322CrossRefPubMed

44.

Avci E, Yildirim T, Aydin G, Kiris T, Dolapoglu A, Kadi H et al (2018) Combining clinical predictors to better predict for the no-reflow phenomenon. Eur Rev Med Pharmacol Sci 22:4987–4994. https://doi.org/10.26355/eurrev_201808_15639CrossRefPubMed

45.

Hashemi-Jazi M, Hosseini SM, Gholamrezaei A (2017) Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts. ARYA Atheroscler 13:221–229PubMedPubMedCentral

46.

Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Tei C et al (2004) The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary interventional era. Ann Med 36:153–160. https://doi.org/10.1080/07853890310021553CrossRefPubMed

47.

Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY et al (2009) Predictors of no-reflow after percutaneous coronary intervention for culprit lesion with plaque rupture in infarct-related artery in patients with acute myocardial infarction. J Cardiol 54:36–44. https://doi.org/10.1016/j.jjcc.2009.03.003CrossRefPubMed

Titel: Association of CHA2DS2-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI
verfasst von: Orhan Maden, MD
Özge Çakmak Karaaslan, MD
Yücel Kanal, MD
İdris Yakut, MD
Nezaket Merve Yaman, MD
Hasan Can Könte, MD
Kevser Gülcihan Balcı, MD
Mehmet Timur Selçuk, MD
Hatice Selçuk, MD
Publikationsdatum: 04.10.2021
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 5/2022
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-021-05070-x

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Erratum to: Outcomes of patients with ST-segment myocardial infarction admitted during the COVID-19 pandemic

First experiences with a new balloon-expandable Myval transcatheter aortic valve: a preliminary study

Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes

Lipidsenkung: neue Substanzen und neue Konzepte